<DOC>
	<DOCNO>NCT02969655</DOCNO>
	<brief_summary>Daprodustat drug currently develop treatment renal anemia . This study evaluate efficacy safety daprodustat follow switch erythropoiesis-stimulating agent ( ESA ) Japanese HD subject renal anemia currently treat ESA . The primary objective demonstrate non-inferiority daprodustat darbepoetin alfa . This study 52-week , Phase III , double-blind , active-controlled , parallel-group , multi-center study . The total duration study approximately 58 week include screen follow-up .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Daprodustat Compared Darbepoetin Alfa Japanese Hemodialysis ( HD ) -Dependent Subjects With Anemia Associated With Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Inclusion Criteria Age ( informed consent ) : &gt; =20 year age Dialysis : On HD hemodiafiltration ( HDF ) give three time weekly least 12 week prior screen ESAs : Use one ESA 10 week prior screen ESA dose : Darbepoetin alfa 10 60 μg per week , epoetin ( include biosimilars ) &lt; =9000 international unit ( IU ) per week , epoetin beta pegol &lt; =250 μg per 4 week Hgb : &gt; =9.5 g/dL &lt; =12.5 g/dL . Determined site use Hgb analyzer Iron parameter : Ferritin &gt; 100 nanogram ( ng ) /millilitre ( mL ) transferrin saturation ( TSAT ) &gt; 20 percent ( screen verification ) Gender ( screen verification ) : Female male Females : Not pregnant [ demonstrate negative human chorionic gonadotropin ( hCG ) serum ] , breastfeeding , meet least one following : • Females nonchildbearing potential defined follow : Premenopausal least one follow plan utilise assist reproductive technique ( e.g. , vitro fertilisation donor embryo transfer ) : History bilateral tubal ligation salpingectomy History hysteroscopic tubal occlusion postoperatively document bilateral tubal obstruction History hysterectomy History bilateral oophorectomy Postmenopausal define A ) females 60 year age old B ) In female &lt; 60 year age , 12 month spontaneous amenorrhea [ questionable case blood sample postmenopausal follicle stimulate hormone ( FSH ) estradiol concentration confirmatory ( see separately specify reference range ) ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one effective contraception method wish continue HRT study . Otherwise must discontinue HRT allow confirmation postmenopausal status prior study enrolment . • Females childbearing potential must agree comply one contraception method list requirement `` GlaxoSmithKline ( GSK ) Listing Most Effective Contraceptive Methods Females Childbearing Potential 28 day prior first dose study medication completion followup visit . Informed consent : Written inform consent , include adherence requirement condition specify consent form protocol , must obtain subject . Exclusion Criteria CKDrelated criterion Kidney transplant : Planned livingrelated kidney transplant study Anemiarelated criterion Aplasia : History bonemarrow hypoplasia pure red cell aplasia Other cause anemia : pernicious anemia , thalassemia , sickle cell anemia , myelodysplastic syndrome Gastrointestinal ( GI ) bleeding : Evidence actively bleed gastric , duodenal , esophageal ulcer disease OR clinically significant GI bleeding within 10 week prior screen period screen Day 1 Cardiovascular diseaserelated criterion Myocardial infarction , acute coronary syndrome , stroke , transient ischemic attack : Diagnosed within 10 week prior screen period screen Day 1 Heart failure : Chronic Class IV heart failure , define New York Heart Association ( NYHA ) functional classification system Corrected QT ( QTc ) Interval ( screen verification ) : QTc &gt; 500 millisecond ( msec ) ; QTc &gt; 530 msec subject bundle branch block Note : QT interval correct use Bazett 's formula ( QTcB ) use , electrocardiogram ( ECG ) mechanically manually read Other diseaserelated criterion : Liver disease ( follow occurs ) : Alanine transaminase ( ALT ) &gt; 2 upper limit normal ( ULN ) Bilirubin &gt; 1.5×ULN ( isolated bilirubin &gt; 1.5 ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) Current unstable active liver biliary disease ( generally define onset ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal/gastric varix , persistent jaundice , cirrhosis ) Malignancy : History malignancy within 2 year prior screen , currently receive treatment cancer , complex kidney cyst &gt; 3 centimeter ( cm ) ( II F , III IV base Bosniak classification ) Concomitant medication study treatmentrelated criterion Iron : Planned use intravenous iron screen phase period Day 1 Week 4 Severe allergic reaction : History severe allergic anaphylactic reaction hypersensitivity excipients investigational product . Drugs supplement : Use plan use prescription nonprescription drug dietary supplement prohibit study period [ prohibit medication : strong inducer inhibitor Cytochrome P450 ( CYP ) 2C8 ] . Prior investigational product exposure : Use investigational agent within 30 day five half live investigational agent ( whichever longer ) Prior treatment daprodustat : Any prior treatment daprodustat treatment duration &gt; 30 day General healthrelated criterion Other condition : Any condition , clinical laboratory abnormality , examination find investigator ( subinvestigator ) considers would put subject unacceptable risk , may affect study compliance prevent understand aim investigational procedure possible consequence study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Daprodustat</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>